Exhaled nitric oxide and its long‐term variation in healthy non‐smoking subjects

Ekroos, Heikki; Tuominen, J. A.; Sovijärvi, Anssi

doi:10.1046/j.1365-2281.2000.00277.x

Cited by 40 publications

(37 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Expiratory air flow and exhaled volume were measured in real time with a pneumotachograph. The measurement procedure has been thoroughly described previously [24]. At least three repeated measurements were made with a slow exhalation from total lung capacity for w15 s and a mean exhalation flow of 0.09-0.12 L?s -1 using a flow resistance created by a resistor (100 cmH 2 O; Model #100R; Hans Rudolph, Kansas City, USA) in order to close the soft palate.…”

Section: Bronchial Challenge Test Methodsmentioning

confidence: 99%

“…The mean value of three determinations, taken at the end of each expiration as a mean of 3 s plateau value, was recorded for the analysis. Values v12.0 parts per billion (ppb) were regarded as normal, those 12.0-14.4 ppb as slightly increased, and values o14.5 ppb as significantly increased [24]. Patients were asked not to smoke for 4 h, not to drink caffeine-containing drinks for 2 h and not to eat a heavy meal just before NO measurements.…”

Section: Bronchial Challenge Test Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Exhaled nitric oxide in specific challenge tests to assess occupational asthma

Piipari¹,

Piirilä²,

Keskinen³

et al. 2002

Eur Respir J

View full text Add to dashboard Cite

Exhaled nitric oxide (NO) is a marker of eosinophilic inflammation of the airway mucosa accompanying changes in the clinical condition of asthma. Allergen exposure has been associated with delayed elevation of exhaled NO. The aim of this study was to assess the asthmatic airway inflammation with exhaled NO measurements during specific bronchial challenge tests with occupational agents.Forty patients with suspected occupational asthma were investigated. Specific bronchial challenge tests were performed with forced expiratory volume in one second or peak expiratory flow follow-up, supplemented by exhaled NO measurements before and 24 h after challenge tests.In active challenges, which induced bronchoconstriction, a significant mean increase of exhaled NO concentration was noted. In patients with a normal or slightly increased (v14.5 parts per billion (ppb)) basal NO level and a late bronchoconstriction, a significant increase in exhaled NO was seen. Patients with a high basal NO level (w14.5 ppb) and a significant bronchoconstriction did not show a significant NO elevation. Challenge tests without bronchoconstriction were not associated with a significant elevation of exhaled NO.Exhaled nitric oxide measurements can be used to indicate the development of airway inflammation accompanying late asthmatic reaction after bronchial challenge tests in patients with a normal or slightly increased basal nitric oxide concentration.

show abstract

Section: Bronchial Challenge Test Methodsmentioning

confidence: 99%

Section: Bronchial Challenge Test Methodsmentioning

confidence: 99%

Exhaled nitric oxide in specific challenge tests to assess occupational asthma

Piipari¹,

Piirilä²,

Keskinen³

et al. 2002

Eur Respir J

View full text Add to dashboard Cite

show abstract

“…Exhalations not meeting ATS requirements were rejected by the system, and the patient was asked to perform new exhalation manoeuvres, until providing three reproducible FeNO values within 10% of each other. The mean FeNO of three acceptable end-expiratory plateau measurements was calculated and recorded [31,32]. Previously specified reference values for adult lifelong never-smokers, according to the distribution of FeNO by similar technique, and exhalation rate depending on age and height, were used [33].…”

Section: Interview and Questionnairesmentioning

confidence: 99%

Repaired oesophageal atresia: respiratory morbidity and pulmonary function in adults

Sistonen¹,

Malmberg²,

Malmström³

et al. 2010

Eur Respir J

117

View full text Add to dashboard Cite

Although after oesophageal atresia (OA) repair in infancy, respiratory problems are common, their natural history remains unclear. We assessed morbidity, pulmonary function (PF), and bronchial hyperresponsiveness (BHR) in adults with repaired OA respiratory.588 patients who underwent surgery for OA during 1947-1985 were identified and those 262 who were alive and had their native oesophagus were included. Respiratory symptoms and respiratory symptom-related quality of life (RSRQoL) were assessed by questionnaire and interview, and the patients underwent spirometry, a histamine challenge test, and an exhaled nitric oxide test. For the questionnaires, we added 287 carefully matched general populationderived controls.Among the 101 (58 male) patients, median age 36 yrs (range 22-56 yrs), respiratory morbidity was significantly increased compared to controls. Patients had more respiratory symptoms and infections, as well as asthma and allergies, and more often impaired RSRQoL (p,0.001 for all). PF tests revealed restrictive ventilatory defect in 21 (21%) patients, obstructive ventilatroy defect in 21 (21%) patients, and both in 36 (36%) patients. A total of 41 (41%) had BHR, and in 15 (15%), it was consistent with asthma. The most significant risk factors for restrictive ventilatory defect were thoracotomy-induced rib fusions (OR 3.4, 95% CI 1.3-8.7; p50.01) and oesophageal epithelial metaplasia (OR 3.0, 95% CI 1.0-8.9; p50.05).After repair of OA, respiratory-related morbidity, restrictive ventilatory defect and BHR extended into adulthood. Nearly half the patients had BHR and over half had a restrictive ventilatory defect. Thoracotomy-induced rib fusions and gastro-oesophageal reflux-associated oesophageal epithelial metaplasia were the strongest risk factors for restrictive ventilatory defect.

show abstract

“…While in healthy people short and long term FeNO variations have been evaluated [16,17], the feasibility of FeNO monitoring in COPD is still unknown.…”

Section: Introductionmentioning

confidence: 99%

Exhaled nitric oxide monitoring in COPD using a portable analyzer

Laurentiis¹,

Maniscalco²,

Cianciulli³

et al. 2008

Pulmonary Pharmacology & Therapeutics

View full text Add to dashboard Cite

A c c e p t e d m a n u s c r i p t 2 ABSTRACT BACKGROUNDExhaled nitric oxide (FeNO) is a non-invasive marker of airway inflammation in asthma. A very recent statement has suggested FeNO as potential outcome in chronic obstructive pulmonary disease (COPD). Recently, a new hand-held FeNO analyzer (NIOX MINO) has been developed. PATIENTS AND METHODSWe have evaluated the NIOX MINO in COPD patients and monitored FeNO levels during 1-year assessment in the outpatient setting. Short-term variability in FeNO was compared using a NIOX MINO and a stationary chemiluminescence analyser (NOA, Sensormedics) in healthy volunteers and COPD patients on two consecutive months. Long-term FeNO variability was assessed on a cohort of 70 COPD outpatients measuring FeNO for one year. The intra-individual FeNO coefficient of variation (eNOCoV) was taken as index FeNO long-term variability. RESULTSIn COPD there were no significant differences between NIOX MINO and NOA FeNO values recorded at baseline and one month later. 95% limits of agreement between NIOX MINO and NOA were -2.7 and 1.9 ppb with significant reliability (r=0.96, p<0.0001). Mean FeNO at baseline was 15.0±9.5 ppb. Over the one year period the overall mean FeNO was 15.5±10.1 ppb. The long term eNOCoV was 33.9±16.4 % (range 8.1-83.1 %), and it was significantly associated with exacerbation rate (r= 0.57, p<0.0001). CONCLUSION

show abstract

Exhaled nitric oxide and its long‐term variation in healthy non‐smoking subjects

Cited by 40 publications

References 22 publications

Exhaled nitric oxide in specific challenge tests to assess occupational asthma

Exhaled nitric oxide in specific challenge tests to assess occupational asthma

Repaired oesophageal atresia: respiratory morbidity and pulmonary function in adults

Exhaled nitric oxide monitoring in COPD using a portable analyzer

Contact Info

Product

Resources

About